Lamivudine for chronic hepatitis B: a brief review
Braz. j. infect. dis
;
12(5): 355-357, Oct. 2008.
Artículo
en Inglés
| LILACS
| ID: lil-505345
ABSTRACT
Until recently, the only generally approved treatment for chronic hepatitis B was alpha-interferon; however, it gives only moderate efficacy in terms of sustained response (biochemical, virological and histological). In fact, only 20 percent to 40 percent of treated patients respond to therapy, with lower percentages (~ 10 percent) among patients infected with precore-mutant strains of HBV (HBeAb HBV-DNA positive). The FDA of the USA approved the use of lamivudine in adult patients affected by chronic hepatitis B in 1998. In this review, we focused on the pharmacokinetic and pharmacodynamic properties and efficacy and tolerability of lamivudine in the treatment of chronic hepatitis B cases that are both HBeAg and anti-HBe-positive.
Texto completo:
Disponible
Índice:
LILACS (Américas)
Asunto principal:
Antivirales
/
Lamivudine
/
Hepatitis B Crónica
Límite:
Humanos
Idioma:
Inglés
Revista:
Braz. j. infect. dis
Asunto de la revista:
Enfermedades Transmisibles
Año:
2008
Tipo del documento:
Artículo
País de afiliación:
Italia
Institución/País de afiliación:
Sondrio Hospital/IT
Similares
MEDLINE
...
LILACS
LIS